DDRE-18. THERAPEUTIC EFFECTS OF TASQUINIMOD ON GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2021 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noab196.302
Abstract: Glioblastoma is the most aggressive and most common primary malignant brain tumor in adults. This disease is still incurable despite multimodal therapies. We evaluated Tasquinimod, an oral HDAC4 inhibitor, in use with oncolytic HSV therapy.… read more here.
Keywords: glioblastoma; therapeutic effect; tasquinimod; tasquinimod glioblastoma ... See more keywords
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-2954
Abstract: Purpose: Glioblastoma (GBM) is the most common primary central nervous system cancer in adults. Oncolytic HSV-1 (oHSV) is the first FDA-approved gene therapy approach for the treatment of malignant melanoma. For GBM, oHSVs need to… read more here.
Keywords: glioblastoma; oncolytic hsv; gbm; treatment ... See more keywords
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
Sign Up to like & getrecommendations! Published in 2021 at "Viruses"
DOI: 10.3390/v13091740
Abstract: Herpes simplex virus (HSV) can be genetically altered to acquire oncolytic properties so that oncolytic HSV (oHSV) preferentially replicates in and kills cancer cells, while sparing normal cells, and inducing anti-tumor immune responses. Over the… read more here.
Keywords: hsv; immunovirotherapy; oncolytic hsv; cancer ... See more keywords